Chugai Pharma Manufacturing Co. Ltd. – FDA 483, Sep 26, 2019
An FDA inspection of Chugai Pharma Manufacturing Co. Ltd. in Utsunomiya, Japan, revealed significant deficiencies in laboratory controls, production systems, and quality control. Repeat observations from previous inspections highlight ongoing issues with data integrity, electronic record management, and the adequacy of visual inspection processes for finished drug products. The firm also failed to adequately investigate product complaints and deviations, indicating a systemic breakdown in quality oversight.
ID · fb1f6419-98cd-4518-a9f4-7ccbaccef3d3
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.